Zenotech Labs: ₹43 Cr Sales, ₹339 Cr Market Cap – Missing DNA Clones, Found P/E of 81
1. At a Glance
Zenotech makes injectables that go into cancer and anesthesia treatments. Sounds cool? Until you see the size: annual sales ₹43 Cr, profits ₹5 Cr. Market cap = ₹339 Cr, meaning you’re paying ₹8 for every ₹1 of sales. The company is almost debt-free, but its independence? Gone — it’s practically a Sun Pharma outsourcing unit. To add spice, court cases exist over missing vehicles, missing records, and even missing DNA clones. If Sherlock Holmes was an equity analyst, he’d call this “The Curious Case of the Vanishing Biotech.”
2. Introduction
Born in 1989, Zenotech was supposed to be India’s biotech rising star. Instead, it became a stepchild of Sun Pharma, producing niche injectables under loan licensing. Overseas subsidiaries? Shut down — Brazil, USA, Nigeria, all gone. Current business? 88% of revenue is “sale of services” (read: contract work for Sun). Facility leasing and machinery leasing bring another 9%.
So basically, the lab is a landlord + contractor rolled into one. Innovation? Maybe. Independence? Nah. The dependency on Sun Pharma is so high, you could call Zenotech “Sun’s Biotech Annexure.”
Question for you: would you pay premium P/E for a company whose boss is basically your counterparty?
3. Business Model (WTF Do They Even Do?)
Zenotech’s “portfolio” is really just a niche injectable workshop.
Oncology injectables (like GCSF, GMCSF).
Anesthesiology injectables.
Rents out biotech facilities and machines for small income.
But here’s the catch: 200 Cr related party deal with Sun Pharma approved for FY22–26. Translation: most of its revenue is tied to Sun’s orders. If Sun gets a cold, Zenotech sneezes.
Think of it like a college project group: Zenotech does the assignments, Sun Pharma presents them in class and takes the grade.
